Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1982 1
1990 1
2006 1
2007 2
2008 1
2012 4
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bahl A, Barton P, Bowers K, Brough S, Evans R, Luckhurst CA, Mochel T, Perry MW, Rigby A, Riley RJ, Sanganee H, Sisson A, Springthorpe B. Bahl A, et al. Among authors: springthorpe b. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6688-93. doi: 10.1016/j.bmcl.2012.08.124. Epub 2012 Sep 15. Bioorg Med Chem Lett. 2012. PMID: 23031591
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part I.
Furber M, Alcaraz L, Luckhurst C, Bahl A, Beaton H, Bowers K, Collington J, Denton R, Donald D, Kinchin E, MacDonald C, Rigby A, Riley R, Soars M, Springthorpe B, Webborn P. Furber M, et al. Among authors: springthorpe b. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7702-6. doi: 10.1016/j.bmcl.2012.09.113. Epub 2012 Oct 23. Bioorg Med Chem Lett. 2012. PMID: 23142617
Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H₁ antagonists. Part II: optimising in vivo clearance.
Furber M, Alcaraz L, Luckhurst C, Bahl A, Beaton H, Bowers K, Collington J, Denton R, Donald D, Kinchin E, MacDonald C, Rigby A, Riley R, Soars M, Springthorpe B, Webborn P. Furber M, et al. Among authors: springthorpe b. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7707-10. doi: 10.1016/j.bmcl.2012.09.112. Epub 2012 Oct 10. Bioorg Med Chem Lett. 2012. PMID: 23116889
From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.
Springthorpe B, Bailey A, Barton P, Birkinshaw TN, Bonnert RV, Brown RC, Chapman D, Dixon J, Guile SD, Humphries RG, Hunt SF, Ince F, Ingall AH, Kirk IP, Leeson PD, Leff P, Lewis RJ, Martin BP, McGinnity DF, Mortimore MP, Paine SW, Pairaudeau G, Patel A, Rigby AJ, Riley RJ, Teobald BJ, Tomlinson W, Webborn PJ, Willis PA. Springthorpe B, et al. Bioorg Med Chem Lett. 2007 Nov 1;17(21):6013-8. doi: 10.1016/j.bmcl.2007.07.057. Epub 2007 Aug 19. Bioorg Med Chem Lett. 2007. PMID: 17827008
Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.
Bahl A, Barton P, Bowers K, Caffrey MV, Denton R, Gilmour P, Hawley S, Linannen T, Luckhurst CA, Mochel T, Perry MW, Riley RJ, Roe E, Springthorpe B, Stein L, Webborn P. Bahl A, et al. Among authors: springthorpe b. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6694-9. doi: 10.1016/j.bmcl.2012.08.103. Epub 2012 Sep 11. Bioorg Med Chem Lett. 2012. PMID: 23021991
13 results